August 12, 2017 3:26pm


Also after the IBB (-2.82%) and IWM (-1.82%) dumped Thursday, they rose from the hole to a positive (IBB +0.15% and IWM +0.64%)


As to the future, some guidance identifies runways yet, G&A spending patterns aren’t changing and development platforms are not pinched


Pre-open indications: 4 hit and 2 miss

A total of twenty-seven (27) of my coverage list reporting to date – review the numbers if a subscriber to validate my findings



It’s called premium content for a reason … I define insight  from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!

Others don’t even come close!


I answer one question, in which company should investors commit and keep their money.



Friday’s results have implications to Thursday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!




From the pre-open’s investor’s newsletter, ‘… buy, sell or beware! Many equities are even cheaper as the risk factors become more glaring. Q2 results identify strengths, continuous weakness, lessening opportunity and more threats. Declining share pricing is sending a message; many are just not hearing it …!

  • Wait until Monday when more reporting continues with a couple of - losers showing their “stuff”!


The REAL issue is … valuations are or have become … PROBLEMATIC – review runways <cash position as to quarterly spending>!!



The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The first hour was positive with an A/DL of 25/13 and 5 flats;

·         The mid-day was positive with an A/DL of 24/18 and 1 flat;

·         The close was positive  with an A/DL of 28/14 and 1 flat;



Pre-open indications:  4 hit and 2 miss

  • Biostage (BSTG) closed down -$0.00 – hit;
  • BioLife Solutions (BLFS) closed up +$0.20 – miss;
  • Capricor (CAPR) closed down -$0.02 – miss;
  • Caladrius Biosciences (CLBS) closed up +$0.10 – hit;
  • Juno Therapeutics (JUNO) closed up +$0.52 – hit;
  • Intrexon (XON) closed down -$0.99 – hit;



Regenerative Medicine Earnings Scorecard - Q2/2017 - to date … 27 out of 43 covered

  • Should have been a subscriber ...!



Daily analytics:

U.S. stocks closed higher on Friday as Wall Street clawed back from a sharp decline in the previous session but the market still posted a weekly loss on lingering geopolitical uncertainties.

  • The Dow rose 14.31 points to close at 21,858.32. The S&P 500 gained 3.11 points, or 0.1%, to end at 2,441.32, supported by a gain in the health-care sector.

The NASDAQ climbed 39.68 points, or 0.6%, to close at 6,256.56.

  • Friday caps a week dogged by escalating tension between the U.S. and North Korea which culminated with President Donald Trump stating that his earlier threat to unleash “fire and fury” on North Korea “maybe wasn’t tough enough.”

The Russell 2000 index of small-cap stocks finished out the week 2.7% lower, its biggest one-week decline since February 2016.

  • Apart from geopolitical worries, blame Q2 result announcement and seasonality for this week’s retreat given August’s record as a weak month for stocks.



The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market … traded at 15.51, down -3.20% …

  • Thursday traded at 16.04, a +44.37% increase…Wednesday traded at 11.19, up +2.10%, Tuesday traded at 11.03, up +11.08%,  Monday traded at 9.93 … down -1% after last Friday traded at 10.03 – down -3.93% …



Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Friday was up +0.15%

·         Thursday -1.82%

·         Wednesday -0.86%

·         Tuesday  -0.31%

·         Monday +0.16%

·         Last Friday  +0.49%

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Friday was up +0.64%

·         Thursday -2.82%

·         Wednesday -0.32%

·         Tuesday -9,94%

·         Monday +0.54%

·         Last Friday +0.33%



The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %’s migrate…

·         Friday’s decliners ranged from -0.46% <KITE> to -11.97% <IMUC> in 14 equities;

·         Thursday’s decliners ranged from -0.31% <KITE> to -11.52% <VSTM> in 33 equities;

·         Wednesday’s decliners ranged from -0.16% <OSIR> to -21.24% <BLCM> in 31 equities;

·         Tuesday’s decliners ranged from -0.46% <BCLI> to -11.11% <CUR> in 28 equities;

·         Monday’s decliners ranged from -0.21% <CLLS> to -16.07% <NWBO> in 17 equities;

·         Last Friday’s decliners ranged from -0.14% <MDXG> to -13.24% <CUR> in 15 equities;



… Look at the percentage’s (%) and spreads …

·         Friday’s gainers ranged from +0.06% <BSTG> to +11.43% <CUR> in 28 equities;

·         Thursday’s gainers ranged from +0.32% <OSIR> to +12.43% <SGMO> in 8 equities;

·         Wednesday’s gainers ranged from +0.71% <KITE> to +13.33% <VCEL> in 10 equities;

·         Tuesday’s gainers ranged from +0.19%  <ONCE> to +5.79% <KITE> in 14 equities;

·         Monday’s gainers ranged from +0.12%  <IMUC> to +30.43% <BSTG> in 22 equities;

·         Last Friday’s gainers ranged from +0.14%  <ONCE> to +13.43% <RENE.L> in 24 equities;



Some of MY working trend lines or indications:

… The greatest volume to the downside:  ISCO, OSIR, MESO, FCSC and AGTC

… Upside volume was weighted to:  CLBS, KOOL, CLLS, AST and VTGN

… Biggest $ downside:  KITE, FCSC, STML, RENE.L and VSTM

… Largest $ upside:  BLUE, XON, ONCE, SGMO and RGNX

… Flat: ADVM



Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.